MarketMoodz
Wells Fargo backs Biogen pivot to immunology and kidney disease, lifts price target to $250
Wells Fargo upgrades Biogen (BIIB) to overweight and raises the price target to $250, signaling confidence in a pivot to immunology and kidney disease. The note argues lupus and AMR programs could diversify revenue away from MS, with catalysts expected in the next 12-18 months.
Key Takeaways
- Target raised to $250, implying ~41% upside from current levels.
- Thesis centers on immunology/kidney pipelines (lupus, AMR) reducing reliance on neurology.
- Near-term catalysts include data readouts for litifilimab, felzartamab, and dapirolizumab in 12-18 months.
- Stock is up ~1% YTD but still lags the broader market amid sector rotation.
People Involved
- Mohit BansalAnalyst, Wells Fargo
Entities Involved
- Biogen Inc. (BIIB)Biotech company pursuing neurology and expanding immunology/kidney pipelines
- Wells Fargo & CompanyBrokerage issuing the upgrade note
MarketMoodz Analysis
The upgrade reframes BIIB as a multi-franchise biotech, with immunology and kidney-disease programs potentially delivering new revenue streams that offset ongoing MS erosion. The Wells Fargo note highlights late-stage data and regulatory timelines for litifilimab, felzartamab, and dapirolizumab as key catalysts that could lift BIIB's value if results prove additive.
Historically Biogen has faced pressure to diversify away from MS after rising competition and patent losses. A successful data push in lupus and AMR would align BIIB with a broader pharma trend toward specialty immunology, potentially attracting new investors and enabling higher multiple multiples. Investors should watch trial outcomes and regulatory milestones over the next 12-18 months for signs of meaningful data that can translate into revenue and earnings upside.
Next catalysts include late-stage immunology/kidney readouts and potential regulatory milestones over the 12-18 month window. If data stabilizes BIIB’s trajectory, the stock could re-rate as investors reweight BIIB away from MS-only exposure toward a diversified immunology/kidney portfolio.
Source: Original Article